Form 4: Guardant Health Director Reports Scheduled Acquisition of Shares Through RSU Vesting

Guardant Health, Inc. Director Meghan V. Joyce reported the scheduled acquisition of 67 shares of common stock through the vesting of restricted stock units on June 4, 2025.

Summary

• Meghan V. Joyce, a Director of Guardant Health, Inc. (GH), reported the scheduled acquisition of 67 shares of common stock.
• The acquisition is set to occur on June 4, 2025, and is a result of the vesting of restricted stock units (RSUs).
• The transaction code 'M' indicates an exercise or conversion of a derivative security.
• The shares will be acquired at a price of $0, consistent with RSU vesting.
• Following this scheduled transaction, Ms. Joyce will directly beneficially own 7,813 shares of common stock.
• The underlying restricted stock units initially vested 25% on August 4, 2022, with the remaining 75% vesting in substantially equal installments on each monthly anniversary of August 4, 2022, over a three-year period.

Sentiment

Score: 7

Explanation: The filing indicates a routine, expected equity compensation event for a director, increasing their direct ownership, which is generally a neutral to slightly positive signal as it aligns insider interests with shareholders. No negative information is present.

Positives

• Director Meghan V. Joyce is scheduled to increase her direct beneficial ownership of Guardant Health common stock by 67 shares.
• The acquisition is due to the vesting of restricted stock units, indicating a pre-scheduled equity compensation event that aligns insider interests with shareholders.

Future Outlook

This Form 4 filing primarily reports a scheduled future transaction related to insider equity compensation and does not provide forward-looking statements or guidance regarding the company's operational or financial performance.

Industry Context

This filing is a routine insider transaction report for Guardant Health, a precision oncology company. Such filings are common across all industries as part of executive and director compensation plans, reflecting the scheduled vesting of equity awards.

Comparison to Industry Standards

• The scheduled vesting of restricted stock units at a $0 exercise price is a standard practice for equity compensation in publicly traded companies, aligning with common industry benchmarks for executive and director remuneration.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholders due to increased direct stock ownership.

Key Dates

Recommendation

Keywords

Guardant Health, GH, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Director Stock Ownership, Equity Compensation